of untreated tyrosinemia include liver and kidney disturbances. Without treatment, tyrosinemia leads to liver failure. Today, tyrosinemia is increasingly...
7 KB (685 words) - 01:50, 27 February 2022
Tyrosinemia type I is a genetic disorder that disrupts the metabolism of the amino acid tyrosine, resulting in damage primarily to the liver along with...
30 KB (3,369 words) - 09:15, 17 November 2023
Tyrosinemia type II is an autosomal recessive condition with onset between ages 2 and 4 years, when painful circumscribed calluses develop on the pressure...
4 KB (298 words) - 22:58, 6 November 2023
the observed liver enzyme activity in FAH deficiency during hereditary tyrosinemia type 1. In humans, this enzyme is mainly expressed in the liver. FAH...
21 KB (2,536 words) - 15:28, 8 July 2024
Tyrosinemia type III is a rare disorder caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), encoded by the gene...
3 KB (160 words) - 22:59, 6 November 2023
disease G6PD deficiency Disorders of amino acid metabolism phenylketonuria tyrosinemia maple syrup urine disease glutaric acidemia type 1 Urea Cycle Disorder...
15 KB (1,517 words) - 07:36, 14 July 2024
effects of hereditary tyrosinemia type 1 (HT-1). It is available as a generic medication. Nitisinone is used to treat hereditary tyrosinemia type 1 (HT-1) in...
10 KB (893 words) - 02:51, 22 June 2024
deficiency of the enzyme in humans can result in what is known as type II tyrosinemia, wherein there is an abundance of tyrosine as a result of tyrosine failing...
8 KB (965 words) - 03:44, 22 December 2023
syndrome Corneodermatosseous syndrome Huriez syndrome Oculocutaneous tyrosinemia Cardiofaciocutaneous syndrome Schöpf–Schulz–Passarge syndrome Acquired...
4 KB (241 words) - 21:28, 6 June 2024
Both lead poisoning and succinylacetone, whose levels are increased in tyrosinemia type I, inhibit ALAD. Therefore, these conditions should also be considered...
11 KB (1,149 words) - 23:17, 20 August 2023